Amylin Pharmaceuticals, Inc.
News and overview for Amylin Pharmaceuticals, Inc.
Human Genome, Vertex, Amylin in play - MarketWatch
MarketWatch | 20 days 9 hours 39 minutes ago
The Dow Jones Industrial Average /quotes/comstock/10w!i:dji/delayed (INDU 9,808, +95.30, +0.98%) advanced about 110 points to 9,822.
Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009
News-Medical.Net | 33 days 20 hours 27 minutes ago
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that new data from its obesity program will be presented at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society, to be held in Washington, D.C. October 24-28. Phase 2 data from the pramlintide/metreleptin combination treatment clinical program will be the subject of a late-breaking oral presentation. Obesity 2009 is one of the largest scientific conferences in the field of obesity.
FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond
News-Medical.Net | 19 days 16 hours 21 minutes ago
Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today issued the following statement in response to the U.S. Food and Drug Administration (FDA) update on BYETTA® (exenatide) injection.
Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity [Press Release]
PRNewswire | 20 days 20 hours 18 minutes ago
Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and...OSAKA, Japan, Nov. 1, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced today...
Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference [Press Release]
PRNewswire | 16 days 22 hours 33 minutes ago
...Nov. 5, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. will be presenting at the 18th Annual Credit Suisse...Affairs, +1-858-754-4443, anne.erickson@amylin.com,both of Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update [Press Release]
PRNewswire | 19 days 23 hours 18 minutes ago
Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R...INDIANAPOLIS, Nov. 2, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., and Eli Lilly and Company today issued the following statement...
Amylin and Takeda to develop and commercialize pharmaceutical products for obesity
News-Medical.Net | 20 days 18 hours 35 minutes ago
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.
Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009 [Press Release]
PRNewswire | 34 days 33 minutes ago
SAN DIEGO, Calif., Oct. 19, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals to Webcast Third Quarter Results [Press Release]
PRNewswire | 40 days 43 minutes ago
...PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. will webcast its Quarterly...642-7272, alice.izzo@amylin.com, orInvestors, Michael...8602, michael.york@amylin.com, both ofAmylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals signs obesity drug deal with Takeda potentially worth over $1 billion
Sun (Baltimore), The | 20 days 12 hours 22 minutes ago
Amylin Pharmaceuticals Inc. says it could potentially receive more than $1 billion from a partnership with Japan's Takeda Pharmaceutical Co. on potential obesity treatments.
Amylin signs weight-loss drug deal with Takeda
Forbes | 20 days 4 hours 11 minutes ago
NEW YORK -- Amylin Pharmaceuticals Inc. says it could potentially receive more than $1 billion from a partnership with Japan's Takeda Pharmaceutical Co. on potential weight-loss treatments.
Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid [Press Release]
PRNewswire | 73 days 5 hours 16 minutes ago
...PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. and Biocon, Limited (NSE...CONTACT: Anne Erickson of Amylin Pharmaceuticals, Inc., +1-858-754-4443...3195, anne.erickson@amylin.com; or Paula Sengupta...
Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board [Press Release]
PRNewswire | 90 days 13 hours 47 minutes ago
...DIEGO, Aug. 24 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. today announced that its Board of Directors has...York, +1-858-458-8602, michael.york@amylin.com, bothof Amylin Pharmaceuticals, Inc.
Amylin signs obesity drug deal with Takeda
Richmond Times-Dispatch (Va.) | 20 days 12 hours 23 minutes ago
NEW YORK (AP) -- Amylin Pharmaceuticals Inc. says it could potentially receive more than $1 billion from a partnership with Japan's Takeda Pharmaceutical Co. on potential obesity treatments.
LILLY (ELI) & COMPANY - STATEMENT ON FDA'S BYETTA (EXENATIDE) INJECTION UPDATE [Press Release]
PRNewswire | 19 days 12 hours 48 minutes ago
Media contacts: Amylin - Anne Erickson
Sign up for BIO SmartBrief
Company Overview
| Company: | Amylin Pharmaceuticals, Inc. |
|---|---|
| Industry: | Pharmaceuticals Manufacturers |
| Website: | http://www.amylin.com |
Amylin Pharmaceuticals helps diabetics gain the upper hand in their battle with the disease. The company makes and markets two injectable diabetes drugs, Byetta and Symlin, that are approved as adjunct therapies to other diabetes treatments such as metformin and insulin. Development partner Eli Lilly markets Byetta worldwide and is responsible for the development of Byetta in international markets. Amylin's US-based sales force co-promotes Byetta with Eli Lilly and markets Symlin on its own. The company is working on other diabetes drugs, including a once-weekly version of Byetta, as well as treatments for obesity.
Key Numbers
| Sales in U.S. Dollars (mil.) | 840.1 (2008) |
|---|---|
| One-year % Growth in Sales | 7.6 (2008) |
| Net Income in U.S. Dollars (mil.) | -315.4 (2008) |
| One-year % Growth in Net Income | 0.0 (2008) |
| Number of Employees | 1,800 (2008) |
| One-year % Growth in Number of Employees | -5.3 (2008) |
| Fiscal Year-End | December |